🇺🇸

US SEC Filing Intelligence

· daily

US Material Events SEC 8-K Filings — April 10, 2026

Across 50 US SEC 8-K filings dated April 10, 2026, overarching themes include a surge in equity capital raises totaling over $520M (e.g., SPAC IPOs at $200M and $150M, private placements up to $75M ATM), numerous executive and board changes (26 instances, predominantly neutral retirements or appointments with no disagreements cited), debt optimizations and credit expansions enhancing liquidity (e.g., Hecla’s $263M note redemption, CoreCivic’s revolver increase to $400M), and SPAC developments amid mixed M&A outcomes like Dynamix’s $50M termination payout. No explicit period-over-period declines reported across filings; instead, positive forward-looking catalysts dominate, such as Phase 3 funding, manufacturing expansions, and acquisition financings, signaling portfolio-level deleveraging and growth capital access. High materiality events (8-10/10) cluster in financings and debt events, implying bullish liquidity trends for small/mid-caps in biotech, mining, and SPACs versus neutral governance churn in larger caps. Sector implications favor opportunistic plays in space/tech (Spire, Everspin) and mining (Hecla), while exec transitions warrant monitoring for continuity risks. Aggregate capital allocation leans shareholder-friendly via buyback-enabling balance sheets and growth investments, with no dividend cuts or insider sales noted.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 10, 2026

Across 50 SEC filings from Dow Jones 30-related and associated entities, proxy season dominates with over 25 DEF 14A/DEFA14A filings announcing AGMs in May-June 2026, focusing on director elections, auditor ratifications, and say-on-pay votes, signaling routine governance but potential for activist interventions. Positive themes include M&A accretion (McCormick/Unilever Foods expected EPS uplift Year 1, $600M synergies), corporate restructurings (Honeywell spin-offs completed SOLS Oct 2025, Aerospace Q3 2026), and financings (Annovis $10M for Alzheimer's Phase 3, Spire $70M for space growth). Period-over-period trends show mixed results: VeriSign revenue +6.4% YoY to $1.66B, Voya adj EPS +22% with $775M excess capital, but declines in Magic Empire revenue -9.8% YoY, FRP Q4 net income -77% YoY, EvoAir Q2 revenue -5% YoY. Capital allocation leans toward returns (Voya $374M shareholder returns) and expansions (CoreCivic revolver +$100M to $400M). No widespread insider trading patterns, but strong AGM vote approvals (Biglari 95% turnout, Onfolio 89-97% approvals) indicate shareholder alignment. Key implications: Watch May catalysts for governance shifts, favor growth stories like Voya/VeriSign amid small-cap weakness.

28 high priority 22 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 10, 2026

Across 50 SEC filings dated April 10, 2026, proxy season dominates with 15+ DEF 14A/DEFA14A filings signaling upcoming AGMs in May (e.g., Plains, Riley, Honeywell), highlighting governance stability but limited financial insights. Period-over-period trends reveal stark contrasts: Li Auto's revenues plunged 22.3% YoY and net income 86.0% YoY, Qudian's revenues cratered 81.1% YoY despite 673% net income surge from non-op gains, while Riley Exploration grew equity 22% and cut debt 32% post-acquisitions. SPAC and M&A activity surges with 5 deals (Constellation $500M equity value, Willow Lane S-4 effective, McCormick-Unilever $600M synergies), alongside deleveraging (Hecla full $263M note redemption) and financings ($10M Annovis, $93M New ERA). Capital allocation leans shareholder-friendly with buybacks (News Corp $1B, Riley $100M), dividend hikes (Riley +5%), and redemptions, but risks emerge in cost cuts (Retractable workforce reduction, Snail 25% fee cut). Sector patterns show energy/mining resilience via debt reduction and M&A, while Chinese firms face revenue headwinds amid robust liquidity. Overall, actionable alpha lies in SPAC catalysts (Apr-May closings), deleveraging plays, and proxy-driven governance watches, with mixed sentiment (18 positive, 24 neutral, 4 negative, 4 mixed).

27 high priority 23 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 10, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary stream (broadly including retail, auto, restaurants), proxy statements dominate (over 20 filings) signaling peak AGM season with neutral sentiment, while 13F-HR reports (9 filings) reveal neutral institutional positioning in ETFs and tech giants like Alphabet, Amazon, NVIDIA. Period-over-period trends show mixed results: revenue declines averaging -4% YoY in reporting firms (FGI -1%, Brownie's -8%), but strong growth in outliers like TWFG (+22% revenue, +44% NI) and Voya (>22% adj EPS growth); NOI slight upticks in real estate plays like FRP (+2% total NOI) contrast multifamily declines. M&A/SPAC activity bullish with advancements like Willow Lane EGM on April 30 and Boost Run Nasdaq listing imminent, alongside positive capital raises (e.g., XPLR $232M loan). Forward-looking catalysts cluster in late April-May 2026 AGMs, with limited insider data but board refreshers indicating governance focus. Overall, neutral-to-mixed sentiment (materiality avg 5-6/10) suggests stable consumer disc positioning amid economic uncertainty, favoring SPAC de-SPACs and growth outliers for alpha.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 10, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (though many span adjacent sectors like financials, energy, and tech), dominant themes include proxy season ramp-up with 20+ DEF 14A/DEFA14A filings highlighting 2025 performance, institutional 13F snapshots showing ETF-heavy portfolios (e.g., S&P 500, Nasdaq premium income), and biotech/pharma revenue pressures offset by clinical wins. Period-over-period trends reveal sharp declines in healthcare biotechs (Akston -99% YoY revenue, Scilex -47% YoY to $30.3M with net loss widening to $374M from $72.8M), contrasted by financial outperformers like Voya (+22% adj EPS, $1B+ earnings) and Velocity (+53.5% net income YoY to $105M). Critical developments: Scilex SP-102 Phase 3 success (p=0.003 primary endpoint), Humana board refresh with healthcare expert, iSpecimen 85% shipping efficiency gain; M&A/capital activity active (Beneficient $8.75M NAV deal, New Era $93.4M offering). Portfolio-level: Margin deterioration in biotechs/pharma (e.g., Octave Insurance Distribution loss to $23.1M from $8.2M), but capital returns strong (News Corp $1B buyback, FREIT $0.10 Q2 dividend); implications favor monitoring May 2026 AGMs for comp/governance votes amid volatility from offerings (Akston IPO, Conexeu direct list).

21 high priority 29 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 10, 2026

Across 50 DEF 14A proxy statements filed around April 10, 2026, a dominant theme is robust 2025 performance in energy, mining, and financial sectors, with 12/50 filings highlighting YoY revenue growth averaging +30% (e.g., Hecla +53%, TWFG +22%), deleveraging (Riley debt -32%, Hecla -50%), and enhanced shareholder returns via dividends (Welltower +10.4%, Riley +5%) and buybacks (Garrett $208M reducing shares >40%, Royalty Pharma $1.2B). Neutral sentiment prevails in 70% of filings focused on routine governance (director elections, auditor ratifications, say-on-pay), but positive outliers like Voya (+22% adjusted EPS, $374M returns) and Seacoast (NIM +10% YoY, 9% loan growth) signal sector strength amid M&A activity (Riley Silverback acquisition +50% locations, Hope Bancorp Territorial entry). Mixed cases (Masco sales/margins down, Octave premiums -6%) reflect macro challenges, with no widespread insider selling but board refreshments (e.g., Honeywell spins, Bausch new directors) indicating strategic shifts. Portfolio-level trends show margin expansion in high-performers (Garrett 14.2% Adj EBIT) vs compression in industrials, setting up May-June 2026 meetings as key catalysts for comp approvals and plan amendments. Implications favor overweighting energy/financials with strong capital returns, monitoring spin-offs like Honeywell Aerospace (Q3 2026), and avoiding underperformers with quorum issues (Vinebrook). Overall, bullish undertone supports tactical buys pre-proxy votes.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 10, 2026

The April 10, 2026 IPO pipeline features 13 S-1 filings dominated by SPACs (Aeon, Alpex, Irenic), biotechs (Seaport, Hemab, Longeveron), and emerging growth companies, with 10 new filings signaling a surge in public market access amid biotech R&D funding needs and SPAC activity. Period-over-period trends reveal widening net losses across biotechs (Seaport +60% YoY to $74.9M, Hemab from $48.7M to $63.9M driven by R&D surges of 164% and 44% YoY respectively), offset by cash infusions from equity raises (Hemab assets doubled to $194.8M). Neutral sentiment prevails in SPACs and most others, with mixed/negative tones in biotechs due to burn rates and compliance risks; positive outliers in Irenic and HawkEye. Portfolio-level patterns include heavy R&D capital allocation in biotechs (6/13 filings), Nasdaq compliance pressures (e.g., Longeveron deadline Sept 21, 2026), and SPAC raises totaling ~$455M+ gross. Market implications point to near-term IPO catalysts but heightened dilution risks (e.g., Seaport 122M post-IPO shares) and going concern doubts, favoring selective SPAC plays over loss-making biotechs.

13 high priority 13 total filings
· daily

Global High-Priority Regulatory Events — April 10, 2026

The 50 filings reveal a bifurcated landscape: Indian companies dominate with regulatory compliance (15+ non-Large Corporate confirmations, neutral), elevated promoter encumbrances (NRB Bearings 73.91% pledged post-refinance, Camlin 77.36% of holdings), insider divestments (Delhivery holding drop 6.76% to 3.55% via 24M share sales), cyber fraud (Yash ₹2.1Cr), and ongoing insolvency (MEP 22nd CoC meeting). US/SEC filings highlight positive M&A/SPAC momentum (Constellation $500M minerals deal H2 2026 close, Willow Lane EGM Apr 30, McCormick-Unilever $600M synergies accretive Yr1), debt reductions (Hecla $263M notes redeemed fully), financings (Annovis $10M Phase 3 Alzheimer's), and board enhancements (Royale, NexMetals). Key period trend: Li Auto revenue -22.3% YoY to RMB 112B, net income -86% to RMB 1.1B, outlier underperformance vs peers. Portfolio-level patterns show Indian industrials/finance liquidity stress (4 high encumbrance cases >50% promoter holdings), US deal flow signaling growth conviction. No broad margin compression/growth trends due to event focus, but capital allocation improves via redemptions/buybacks (Riley debt -32%, $100M repurchase). Implications: Avoid Indian pledge-heavy names short-term, target US M&A catalysts for alpha.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 10, 2026

Across 22 filings in the Financial Results & Earnings stream, sentiment is predominantly mixed (15/22), with negative tones in retail (Childrens Place -12.8% sales YoY, FGI -1% rev), media (Cumulus -10.3% rev), and digital assets (GD Culture -96.3% cash QoQ), offset by growth outliers like Simulations Plus (+8.3% Q rev YoY, +47.5% NI) and ASP Isotopes (+475% rev). Period-over-period trends show revenue declines averaging -10% YoY in 12/22 companies, but net losses narrowing in 14/22 via cost cuts (e.g., EvoAir op ex -65%, Brownie's working capital +240%), alongside persistent cash burn (16/22 declining cash positions) and equity dilutions (e.g., Balance Labs shares +100%). Capital allocation leans toward financing inflows and equity issuances over dividends/buybacks, with no splits noted; operational metrics highlight R&D surges in biotech/pharma (Quince +90%, Scilex +115%, Stimcell +7316% Q). Portfolio-level implications include sector rotation from consumer/retail to niche tech/services, with alpha in loss-narrowing turnarounds amid high materiality (avg 8/10). No explicit forward-looking guidance or insider trades reported, but trial successes (Scilex SP-102 Phase 3 met endpoints) signal catalysts; watch for cash sustainability in microcaps.

22 high priority 22 total filings
· daily

US SEC Trading Suspension Halt Orders — April 10, 2026

A cluster of six Nasdaq-listed microcap companies received deficiency notices on April 7, 2026, primarily for failing the $1.00 minimum bid price requirement over 30 consecutive business days (Feb 23-Apr 6, 2026) or stockholders' equity below $2.5M as of Dec 31, 2025, signaling acute delisting risks across emerging growth firms. Four filings highlight bid price non-compliance, with three ineligible for standard 180-day extensions due to prior reverse stock splits (DevvStream, Beyond Air, SCWorx), while two face equity shortfalls (Caring Brands at $2.09M vs $2.5M req., Callan JMB below $2.5M). No positive period-over-period financial trends evident; persistent sub-$1 bids reflect YoY/QoQ share price deterioration amid weak fundamentals. SCWorx faces imminent trading suspension on April 14 post failed 180-day extension from 2025 notice. Portfolio implications include heightened volatility, potential OTC delistings, and liquidity evaporation for small-cap holders; no bullish insider activity or capital returns noted, all sentiments negative with high materiality (9-10/10).

6 high priority 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 10, 2026

Across 35 8-K filings in the USA Corporate Distress & Bankruptcy stream (April 10, 2026 period), distress signals dominate with 8 companies facing Nasdaq delisting risks due to sub-$1 bid prices (e.g., DevvStream, Beyond Air, SCWorx), low stockholders' equity (Caring Brands, Callan JMB), or MVLS/net income failures (Alpha Modus), reflecting microcap vulnerability amid no explicit YoY/QoQ declines but inferred weak performance from compliance breaches post-reverse splits. Countervailing trends include 12+ capital raises/ATM offerings/debt amendments (e.g., Spire Global $70M PP, Annovis $10M offering, CoreCivic revolver to $400M), signaling aggressive liquidity pursuits to avert bankruptcy. No outright bankruptcies or going-concern warnings, but lease terminations (Lyra Therapeutics $4.4M cost) and deal terminations (Dynamix SPAC) highlight cost-cutting/restructuring. Positive outliers like Hecla Mining's $263M debt redemption and Venture Global's $1.75B refinancing unlock flexibility, while mixed sentiments prevail (14/35 neutral/mixed). Portfolio-level pattern: 40% filings show financing activity vs. 23% delisting risks, with no insider trading or dividend/buyback data but forward catalysts clustered April 10-15 closings. Implications: Short-term volatility in Nasdaq microcaps; opportunities in refinancings for turnaround plays.

35 high priority 35 total filings
· daily

US Executive Officer Management Changes SEC — April 10, 2026

Across 39 filings on executive and director changes dated April 10, 2026, the dominant theme is board refreshment with 14 directors announcing non-re-election or retirement (e.g., NexMetals, Expand Energy, Cypherpunk's 4 directors), typically without disagreements, signaling proactive governance amid 2026 AGMs. Positive appointments of seasoned executives dominate in energy/mining (NexMetals' Rio Tinto vet, Royale's petroleum geologist), tech/fintech (Remitly's ex-Twitter CTO), and industrials (Caterpillar's internal CFO successor post-record $67.6B FY2025 sales), boosting sentiment in 9 cases. Retention and amended agreements (Immunic CEO bonus $670K, Longeveron RSU grants post-financing, Playboy RSUs vesting 2027-2028) highlight efforts to retain talent amid transitions, with 7 CFO/PAO changes (e.g., Expand, Kalaris, Regional Health) mostly neutral but interim leadership in smaller firms raising execution risks. No broad period-over-period deteriorations noted, but sector-specific strengths emerge like Caterpillar's YoY sales records vs. biotech churn (Vir, Immunic). Capital allocation leans toward equity incentives (PodcastOne plan doubled to 4M shares, Cherry Hill LTIP $900K target for CEO), with no dividend/buyback shifts. Overall, low materiality (avg 5.5/10) suggests limited immediate volatility, but clustered AGMs and C-suite handovers create near-term catalysts for governance scrutiny and stock reactions.

39 high priority 39 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 10, 2026

Across 39 filings on USA Board Room Changes from April 10, 2026, dominant themes include board refreshment via retirements/non-re-elections (17 cases, e.g., NexMetals, Cypherpunk, Expand Energy) and new appointments of experienced executives/directors (12 cases, e.g., Remitly, Humana, Caterpillar), with neutral sentiment prevailing (70% of filings) signaling routine transitions rather than distress. Positive signals emerge in strategic hires like Remitly's ex-Twitter CTO and Caterpillar's internal CFO succession amid record $67.6B FY2025 sales, while mixed/negative notes in biotech (Immunic CEO transition, Vir Biotech CMO exit) highlight commercialization pivots. No widespread period-over-period deteriorations noted, but capital allocation trends show increased equity incentives (RSUs/options in 10 filings, e.g., PodcastOne doubling share pool to 4M, Longeveron restoring salaries + 250k-500k RSUs post-financing). Executive retention/transition packages (9 cases, e.g., Bruker $1M severance, Hawaiian Electric $200k/mo consulting) indicate stability focus amid talent wars. Portfolio-level implication: Biotech/healthcare sees highest churn (10/39, avg materiality 6.5/10), REITs emphasize comp benchmarking (Cherry Hill, Innovative Industrial), with AGMs cluster in May-June 2026 as catalysts. Overall, low disruption risk but watch for post-AGM board impacts on strategy.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — April 10, 2026

The 14 filings reveal a surge in SPAC activity with 5 new IPOs/extensions/appointments signaling renewed M&A appetite in blank-check vehicles targeting tech, private credit, and advanced materials, amid 3 director resignations and 1 delisting highlighting sector churn. Actual M&A progressed with BiomX's acquisition of Zorronet (AI defense tech) from Nukkleus, FG Merger's Boxabl deal extension to July 31, 2026, and Compass Digital's merger with Key Mining, while Ashford Hospitality's $40.5M hotel sale improved pro forma operating income 18.5% YoY to $137.9M and narrowed net loss 10.7% to $(191.8M). Jet.AI's 1-for-200 reverse split reduced shares 99.5% to maintain Nasdaq compliance, freeing shares for potential future deals. No broad insider trading activity noted, but board additions in Iron Horse, T-REX convey management conviction; sentiments skew positive/neutral (10/14) with SPAC governance tweaks dominating. Portfolio-level trends show asset sales/debt reductions enhancing balance sheets (e.g., Ashford net debt -1.6% pro forma), positioning for M&A catalysts. Distressed signals in Quetta (MVLS failure post-180 days) contrast bullish IPO momentum ($350M+ raised), implying selective opportunities in dealflow-ready SPACs vs. fading ones.

14 high priority 14 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 10, 2026

Overnight SEC filings highlight a surge in proxy statements (15+ filings) signaling peak proxy season with AGMs clustered in May-June 2026, alongside active M&A/SPAC activity (McCormick-Unilever combo, Willow Lane-Boost Run, Constellation-HiTech) promising synergies and listings. Energy/mining sectors show deleveraging strength: Hecla redeemed $263M notes for unencumbered balance sheet, Riley cut debt 32% post-acquisitions with equity +22% YoY and $100M buyback. Financial results mixed: Li Auto revenues -22.3% YoY and NI -86% YoY, Qudian revenues -81.1% YoY despite NI +673% on non-op income, contrasting Welltower's 14.1% YoY NOI growth and 228.2% cumulative TSR 2021-2025. Capital allocation favors shareholders with dividend hikes (Riley +5%, Welltower +10.4%) and buybacks (News Corp $1B program, Riley $100M). No widespread insider selling patterns, but board refreshers indicate governance focus; forward catalysts include earnings previews and de-SPAC closings H2 2026. Portfolio trend: Positive sentiment dominates (25+ bullish/neutral), with outliers in China-exposed autos/fintech dragging, implying overweight energy/REITs ahead of catalysts.

27 high priority 23 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 09, 2026

The FDA approved 17 other products from April 2-6, 2026, with 0 NMEs, 0 biosimilars, 0 label expansions, and all 17 neutral signals in the biotech small-cap stream. A clear dominant theme emerges from clustering: 9 approvals for dapagliflozin across Alembic, Aurobindo Pharma, Micro Labs, Ajanta Pharma Ltd, Macleods Pharms Ltd, Lupin Ltd, Torrent, MSN, and Cipla, alongside 3 approvals for nintedanib esylate by Cipla, Dr Reddys, and Sandoz. Highest-conviction signal is the dapagliflozin cluster (e.g., Cipla and Lupin Ltd approvals), representing bullish entry opportunities for these small-cap generic sponsors into a mature market, balanced by originator revenue erosion risks. Additional singles include glycopyrronium tosylate (Padagis US), phenylephrine hydrochloride (Baxter Hlthcare Corp), and three unknowns (Sandoz Inc, Biocon Pharma Ltd, Inventia Hlthcare). Key risk/watch item: intense multi-sponsor competition in dapagliflozin and nintedanib, potentially compressing entrant margins despite neutral signals.

17 total filings
· daily

New Drug Approvals (Original) — April 09, 2026

The FDA recorded 17 'Other' new drug approvals from April 2-6, 2026 (period defined as April 9), comprising 0 NMEs, 0 biosimilars, 0 label expansions per mix breakdown, with all individual analyses labeled as neutral fallback biosimilar approvals and lacking commercial data. A clear dominant theme emerges in clustered generic/biosimilar entries for dapagliflozin (9 approvals to Alembic, Aurobindo Pharma, Micro Labs, Ajanta Pharma Ltd, Macleods Pharms Ltd, Lupin Ltd, Torrent, MSN, Cipla) and nintedanib esylate (3 approvals to Cipla, Dr Reddys, Sandoz), signaling heightened competition in cardiorenal-metabolic and idiopathic pulmonary fibrosis markets. Highest-conviction signal is the dapagliflozin cluster, bullish for entrant sponsors like Cipla and Lupin Ltd as execution signals in complex generics, bearish for originator AstraZeneca with potential 30-60% Farxiga revenue erosion over 2-3 years. Additional singles include glycopyrronium tosylate (Padagis US), phenylephrine hydrochloride (Baxter Hlthcare Corp), and three unknowns (Sandoz Inc, Biocon Pharma Ltd, Inventia Hlthcare). Key risk/watch item: competitive intensification from multiple dapagliflozin entrants, monitor originator revenue trajectories and generic launch timelines.

17 total filings
· daily

Federal Construction & Infrastructure Contracts — April 09, 2026

These two civilian federal construction contracts total $218,304,799 in obligations, with 0/2 defense-related and focus on Department of Transportation (DOT) and Department of Homeland Security (DHS) infrastructure projects. The highest materiality award is a bullish $95,538,222 firm fixed price delivery order to Brasfield & Gorrie LLC from the U.S. Coast Guard for utility infrastructure, roads, and clinic construction at USCG Base Charleston, SC, signaling substantial medium-term revenue under full and open competition. Kokosing Construction Company, Inc. received a neutral $122,766,577 contract modification from DOT, lacking detailed competitive or risk signals. Dominant theme is civilian agency infrastructure buildout with no defense exposure. Highest-conviction signal is bullish growth for Brasfield & Gorrie amid 3.25-year performance period starting April 2026. Key watch item is Brasfield & Gorrie's outlay progress from $0 current amid high firm fixed price execution risk.

2 total filings
· daily

DHS Homeland Security Contracts — April 09, 2026

DHS awarded $152,669,403 in obligations across two civilian contracts during April 09-09, 2026, with zero defense-related activity. The dominant theme is U.S. Coast Guard infrastructure investment, led by a $95.5 million firm fixed-price design-build contract to Brasfield & Gorrie LLC for utility, roads, and clinic construction at USCG Base Charleston, SC. This full and open competition award provides the highest-conviction bullish signal for Brasfield & Gorrie, estimating ~$29 million annual revenue over 3.25 years starting April 2026. A neutral $57.1 million modification to Paragon Professional Services LLC adds lesser materiality. Key watch item: Brasfield & Gorrie's outlay progress from $0 current obligation amid high firm fixed-price execution risk.

2 total filings
· daily

VA Healthcare & Services Contracts — April 09, 2026

SALIENT CRGT, INC. was awarded a single $205,535,562 firm fixed price Delivery Order by the Department of Veterans Affairs' Technology Acquisition Center NJ for IT network engineering and support services, comprising 100% civilian VA Healthcare & Services obligations with 0 defense-related contracts. The neutral signal (6/10 strength, 7/10 materiality) reflects a competitive full and open win under NAICS 541512, with $101,120,213 already outlayed over ~3 years of the ~5-year period ending 2026-06-21 (potential 2026-09-21), implying ~$41M annual revenue. Substantial subcontracting ($269,012,748 across 43 subawards exceeding prime obligation) tempers direct revenue capture. Highest-conviction signal is established revenue visibility from outlays. Key risk is high pricing risk on the firm fixed price structure amid elevated subawards.

1 total filings